$7.93
4.23% today
Nasdaq, Dec 30, 10:04 pm CET
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Novavax, Inc. Target price 2024 - Analyst rating & recommendation

Novavax, Inc. Classifications & Recommendation:

Buy
50%
Hold
33%
Sell
17%

Novavax, Inc. Price Target

Target Price $16.00
Price $8.28
Potential
Number of Estimates 6
6 Analysts have issued a price target Novavax, Inc. 2025 . The average Novavax, Inc. target price is $16.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 3 Analysts recommend Novavax, Inc. to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Novavax, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Novavax, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 983.71 684.07
50.36% 30.46%
EBITDA Margin -38.00% -37.70%
22.32% 0.79%
Net Margin -88.08% -33.40%
29.45% 62.08%

6 Analysts have issued a sales forecast Novavax, Inc. 2024 . The average Novavax, Inc. sales estimate is

$684m
Unlock
. This is
22.72% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$697m 21.21%
Unlock
, the lowest is
$674m 23.87%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $984m 50.36%
2024
$684m 30.46%
Unlock
2025
$557m 18.55%
Unlock
2026
$652m 17.02%
Unlock
2027
$495m 24.08%
Unlock
2028
$542m 9.54%
Unlock

2 Analysts have issued an Novavax, Inc. EBITDA forecast 2024. The average Novavax, Inc. EBITDA estimate is

$-258m
Unlock
. This is
6.06% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-251m 3.22%
Unlock
, the lowest is
$-265m 8.91%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-374m 39.29%
2024
$-258m 31.00%
Unlock
2025
$-47.3m 81.66%
Unlock
2026
$40.1m 184.80%
Unlock

EBITDA Margin

2023 -38.00% 22.32%
2024
-37.70% 0.79%
Unlock
2025
-8.49% 77.48%
Unlock
2026
6.15% 172.44%
Unlock

6 Novavax, Inc. Analysts have issued a net profit forecast 2024. The average Novavax, Inc. net profit estimate is

$-228m
Unlock
. This is
36.87% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-183m 49.56%
Unlock
, the lowest is
$-272m 24.78%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-866m 35.75%
2024
$-228m 73.63%
Unlock
2025
$16.3m 107.13%
Unlock
2026
$153m 842.01%
Unlock
2027
$155m 1.30%
Unlock
2028
$87.3m 43.82%
Unlock

Net Margin

2023 -88.08% 29.45%
2024
-33.40% 62.08%
Unlock
2025
2.92% 108.74%
Unlock
2026
23.52% 705.48%
Unlock
2027
31.38% 33.42%
Unlock
2028
16.10% 48.69%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -5.41 -1.43
35.75% 73.57%
P/E negative
EV/Sales 0.93

6 Analysts have issued a Novavax, Inc. forecast for earnings per share. The average Novavax, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.43
Unlock
. This is
36.73% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.14 49.56%
Unlock
, the lowest is
$-1.70 24.78%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-5.41 35.75%
2024
$-1.43 73.57%
Unlock
2025
$0.10 106.99%
Unlock
2026
$0.96 860.00%
Unlock
2027
$0.97 1.04%
Unlock
2028
$0.55 43.30%
Unlock

P/E ratio

Current -3.66 363.29%
2024
-5.80 58.47%
Unlock
2025
81.44 1,504.14%
Unlock
2026
8.65 89.38%
Unlock
2027
8.54 1.27%
Unlock
2028
15.19 77.87%
Unlock

Based on analysts' sales estimates for 2024, the Novavax, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.72 380.00%
2024
0.93 29.85%
Unlock
2025
1.15 22.78%
Unlock
2026
0.98 14.55%
Unlock
2027
1.29 31.72%
Unlock
2028
1.18 8.70%
Unlock

P/S ratio

Current 1.50 161.68%
2024
1.94 29.40%
Unlock
2025
2.38 22.78%
Unlock
2026
2.03 14.55%
Unlock
2027
2.68 31.72%
Unlock
2028
2.45 8.71%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today